Endoscopic sleeve gastroplasty using Apollo Overstitch as a bridging procedure for superobese and high risk patients

In some cases, bariatric procedures cannot be performed via laparoscopic or open surgery because of surgical contraindications or high operative risk. Endoscopic sleeve gastroplasty (ESG) using an Overstitch (Apollo Endosurgery, Austin, Texas, USA) is a recently described procedure [1, 2] with good preliminary 1-year results in small series and low complication rates [3–5] for patients with a body mass index (BMI) ranging from 30–45 kg/m². However, the routine use of ESG for superobese and high risk patients has not yet been described. The indications for ESGs performed in five superobese patients in our institution were as follows: (i) surgically impenetrable abdomen due to multiple operations or a giant incisional hernia; (ii) future liver or kidney transplant recipient; (iii) high risk patient with a contraindication to operation; (iv) a bridging procedure in a two-step concept (the first endoscopic, the second surgical 12–18 months later). Patients with BMI ranging from 51–72 kg/m² with numerous co-morbidities were submitted to ESG after multidisciplinary evaluation.

With the patient under general anesthesia and after installation of an overtube (Apollo Endosurgery), ESG was per-
formed using a standard two-channel endoscope (GIF-H180) with the patient intubated and in a supine position because of difficult ventilation (▶ Fig. 1; ▶ Video 1). Using CO2 insufflation, a pattern of six stitches was performed for each suture, starting from the incisura and progressing proximally to the gastroesophageal junction (▶ Fig. 2). The tubular construction of the gastroplasty was obtained after five to eight sutures, while closure of the upper fundus was avoided (▶ Fig. 3 and ▶ Fig. 4).

The operative time ranged from 93 to 230 minutes and there were no complications. Patients resumed a liquid diet on the same day and were discharged on postoperative day 3. At 3-month follow-up, the patients had lost 17–56 kg (mean 34.5 kg) resulting in a mean reduction of BMI from 58.6 to 52.5 kg/m². ESG for superobese and high risk patients offers a potential alternative therapy for bridging or a primary morbid obesity therapy.

Competing interests

Ricardo Zorron is a member of the Scientific Advisory board (SAB) of Apollo.

The authors

Ricardo Zorron1, Wilfried Veltzke-Schlieker2, Andreas Adler2, Christian Denecke1, Tomasz Dziodzio1, Johann Pratschke1, Christian Benzing1

1 Center for Bariatric and Metabolic Surgery, Center for Innovative Surgery – ZIC, Department of Surgery, Charité – Universitätsmedizin Berlin, Campus Charité Mitte and Campus Virchow-Klinikum, Berlin, Germany
2 Medical Department, Division of Hepatology and Gastroenterology, Interdisciplinary 11 Endoscopy, Charité-Universitätsmedizin Berlin, Berlin, Germany

Corresponding author

Ricardo Zorron, MD
Center for Bariatric and Metabolic Surgery, Center for Innovative Surgery – ZIC, Department of Surgery, Charité – Universitätsmedizin Berlin, Campus Charité Mitte and Campus Virchow-Klinikum, Augustenburger Platz 1, Berlin, Germany
ricardo.zorron@charite.de

References


Bibliography
DOI https://doi.org/10.1055/s-0043-119685
Published online: 17.10.2017
Endoscopy 2018; 50: E81–E83
© Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0013-726X